MannKind (MNKD) – Major News
-
MannKind (MNKD) Tops Q4 EPS by 2c
-
MannKind (MNKD) Tops Q3 EPS by 4c
-
MannKind (MNKD) Tops Q2 EPS by 4c
-
MannKind (MNKD) Tops Q1 EPS by 1c
-
MannKind (MNKD) Misses Q4 EPS by 2c
-
MannKind (MNKD) Reports In-Line Q1 EPS
-
MannKind (MNKD) Q4 Revenues Rise 254%; Achieves First Ever Qtr Afrezza Gross Profit
-
MannKind (MNKD) Reports Q1 Loss of $0.25/Share
-
MannKind (MNKD) Restructures, Reduces Debt by $14.5M
-
MannKind (MNKD) Tops Q4 EPS by 1c, Revs Beat
-
MannKind (MNKD) Misses Q3 EPS by 11c
-
MannKind (MNKD) Misses Q2 EPS
-
MannKind (MNKD) Misses Q1 EPS by 8c
-
MannKind (MNKD) Tops Q4 EPS by 73c
-
MannKind (MNKD) Posts Q3 EPS of 26c, Topping Views
-
MannKind (MNKD) Misses Q2 EPS by 1c
-
MannKind (MNKD) Misses Q1 EPS by 2c
-
MannKind (MNKD) Posts Q4 Loss of 66c/Share
-
MannKind (MNKD) Said Exploring Possible Sale
-
MannKind (MNKD) Enters Into Collaboration and License Agreement with Receptor Life Sciences
-
MannKind (MNKD) Says DeSisto Won't Be President & CEO; Names Matthew Pfeffer as CEO
-
MannKind (MNKD) Withdraws CEO Offer to Duane DeSisto; Matthew Pfeffer to Assume Role
-
MannKind (MNKD) Announces Termination of Licensing Agreement with Sanofi (SNY); Will Evaluate Options for Afrezza
-
MannKind (MNKD) Announces Termination of Its License Agreement With Sanofi (SNY)
-
MannKind (MNKD) Names Duane DeSisto as President and CEO
-
MannKind (MNKD) CEO Edstrom Steps Down
-
MannKind (MNKD) Misses Q3 EPS by 1c
-
MannKind (MNKD) Tops Q2 EPS by 1c
-
MannKind (MNKD) Reports In-Line Q1 Loss of 8c/Share
-
MannKind (MNKD) CEO Alfred Mann to Retire; Will Transition to Executive Chairman
-
MannKind (MNKD) Posts Q3 Loss of 9c/Share
-
Mannkind Corp (MNKD) Posts Q2 Loss of 19c/Share
-
MannKind (MNKD) Inks Afrezza Licensing Agreement with Sanofi (SNY)
-
MannKind (MNKD) Wins FDA Approval for Afrezza Inhaled Insulin; Will Require Post-Marketing Studies
-
Mannkind Corp (MNKD) Posts Q1 Loss of 14c/Share
-
MannKind (MNKD): FDA Advisory Committee Recommends Approval of AFREZZA(R)
-
Mannkind (MNKD) Confirms FDA Panel Backs AFREZZA for Diabetes
-
Mannkind Corp (MNKD) Posts Q4 Loss of 16c/Share
-
Mannkind Corp (MNKD) Posts Q3 Loss of 17c/Share
-
Mannkind Corp (MNKD) Misses Q2 EPS by 2c
-
Mannkind Corp (MNKD) Reports In-Line Q1 EPS
-
Mannkind Corp (MNKD) Posts Q4 Loss of 23c/Share
-
Mannkind Corp (MNKD) Tops Q3 EPS by 2c
-
Mannkind Corp (MNKD) Posts Q2 Loss of 23c/Share
-
Mannkind Corp (MNKD) Posts Q1 Loss of 27c/Share
-
Mannkind Corporation (MNKD) Tops Q4 EPS by 2c
-
Mannkind Corporation (MNKD) Posts Q3 Loss of $0.31
-
Mannkind Corp. (MNKD) Posts Wider than Expected Q2 Loss
-
Mannkind Corporation (MNKD) Posts Q1 Loss of $0.34, Misses Views
-
MannKind Corp. (MNKD) Posts Narrower than Expected Q4 Loss
Back to MNKD Stock Lookup